Apolipoprotein B: The Cholesterol Number That Matters More Than LDL — and Why Most Men Aren't Testing It

You have probably had your cholesterol checked. The standard panel — total cholesterol, HDL, LDL, triglycerides — has been the front line of cardiovascular screening for forty years. Your primary care doctor reads the LDL number, decides whether you should be on a statin, and that is the conversation. The trouble is that the LDL number, on its own, is meaningfully misleading for a substantial share of men. The metric that actually predicts heart attack risk with the highest reliability is apolipoprotein B — ApoB — and most men have never been tested for it.

This is not fringe science. The European Atherosclerosis Society, the Canadian Cardiovascular Society, and a growing chorus within the American College of Cardiology have shifted the recommended primary lipid target toward ApoB over the past five years. The shift is happening more slowly in everyday primary care, in part because the test costs slightly more, in part because the lab industry has been slow to standardise reporting. The men who ask for ApoB get it. Most men don't ask.

What ApoB actually measures

To understand why ApoB matters, you need to understand what cholesterol particles actually do in the blood. Cholesterol does not float freely in plasma; it is carried inside particles called lipoproteins. The major lipoprotein classes are LDL (low-density lipoprotein), VLDL (very-low-density lipoprotein), IDL (intermediate-density lipoprotein), and Lp(a). Every one of these atherogenic particles — the particles that drive plaque formation in arteries — carries exactly one molecule of apolipoprotein B on its surface.

This means the ApoB measurement gives you a direct count of how many atherogenic particles are circulating in your blood. The LDL cholesterol measurement, by contrast, gives you the total mass of cholesterol carried inside those particles — which is informative but not the same thing. Two men with identical LDL values can have very different ApoB values, depending on whether their LDL particles are large and cholesterol-rich (lower particle count for the same cholesterol mass) or small and cholesterol-poor (higher particle count for the same cholesterol mass). The man with the higher particle count has materially higher cardiovascular risk, even though his LDL number looks identical.

The most important consequence is for patients with metabolic dysfunction, type 2 diabetes, or insulin resistance. These patients tend to produce small, dense LDL particles. Their LDL cholesterol values can read as borderline or even normal while their ApoB values reveal genuinely elevated atherogenic particle counts. The standard panel misses them. ApoB does not.

The evidence base

The decisive comparison studies came from a series of papers published between 2018 and 2023, with the largest contributors being the EPIC-Norfolk cohort, the Copenhagen General Population Study, and a 2022 individual-participant meta-analysis published in the Lancet. Across pooled data from approximately 380,000 patients with twenty-year cardiovascular outcome tracking, ApoB outperformed LDL cholesterol as a predictor of cardiovascular events in head-to-head comparison. ApoB also outperformed non-HDL cholesterol — the second-line metric that has been the alternative recommendation in some guidelines.

The effect size is meaningful but not dramatic. ApoB is roughly 10–15% better at risk discrimination than LDL across the average patient population. In subgroups with insulin resistance or metabolic syndrome — currently estimated at 35–40% of adult U.S. men — the gap is substantially larger. For these patients, the ApoB measurement is genuinely informative in a way that the LDL value isn't.

Lp(a): the second hidden risk factor

While we're on the topic, the other lipid measurement that should be ordered at least once in adult life is Lp(a) — lipoprotein little-a. Lp(a) is a genetically determined particle whose blood level is essentially fixed from birth and barely responsive to lifestyle or to most cholesterol-lowering drugs. Approximately 20% of the global population carries elevated Lp(a) — over 50 mg/dL or 125 nmol/L — and elevated Lp(a) is an independent risk factor for premature cardiovascular disease that is invisible to a standard lipid panel.

The current recommendation is that every adult should have Lp(a) measured at least once between ages 20 and 50. Once measured, the value is essentially stable across decades and the result either pushes you into a higher-intensity prevention strategy or it doesn't. Most adult men have not been tested. The test costs around $40 in 2026 and is increasingly covered by U.S. private insurance.

What the targets should be

The ApoB target depends on your overall cardiovascular risk profile. The current consensus from the European Atherosclerosis Society and similar bodies in 2026:

• Low-risk adults: ApoB below 100 mg/dL
• Moderate-risk adults: ApoB below 80 mg/dL
• High-risk adults (existing cardiovascular disease, type 2 diabetes, familial hypercholesterolaemia): ApoB below 65 mg/dL
• Very high-risk adults (existing CVD with multiple risk factors): ApoB below 55 mg/dL

The aggressive end of these targets reflects an emerging consensus in preventive cardiology that "lower is better" for ApoB across most of the achievable range — that no clear floor exists below which further reduction stops adding benefit. This is a meaningful shift from the conservative 1990s "treat to LDL of 100" thinking.

How to lower ApoB

The interventions that lower ApoB are largely the same interventions that lower LDL — but with some particle-count-specific nuances that matter.

The first-line intervention is statin therapy. A moderate-intensity statin (rosuvastatin 10 mg or atorvastatin 20 mg) reduces ApoB by approximately 35–45%, comparable to its effect on LDL. The newer high-intensity statins (rosuvastatin 40 mg, atorvastatin 80 mg) reduce ApoB by 50–55%. Statin response varies meaningfully across individuals due to genetic factors, and switching between statin types is the standard approach for non-responders.

The second-line additive intervention is ezetimibe, a non-statin agent that blocks intestinal cholesterol absorption. Adding ezetimibe to a statin produces an additional 15–20% ApoB reduction with minimal side-effect profile. The combination is now a standard recommendation for high-risk patients who don't reach target on statin alone.

The third-line intervention, for high-risk patients failing dual therapy, is a PCSK9 inhibitor — the injectable monoclonal antibody class introduced commercially in 2015. Evolocumab (Repatha) and alirocumab (Praluent) are the two market leaders. Adding a PCSK9 inhibitor to maximally tolerated statin plus ezetimibe produces an additional 50–60% ApoB reduction. The cost has dropped substantially since the original 2015 launch — current annual list price in the U.S. is approximately $5,800, with most private insurers covering the drug for high-risk patients meeting clinical criteria. Bempedoic acid, a smaller-effect non-statin oral agent, fills a niche for patients who genuinely cannot tolerate statins.

The lifestyle floor

Lifestyle interventions reduce ApoB by 5–15% in motivated patients, with the largest effects coming from weight loss (in patients with metabolic syndrome), reduction in saturated fat intake, increased fibre intake (particularly soluble fibre from oats, beans, lentils), and increased physical activity. The ceiling is real — a man with genetic ApoB elevation will not normalise on lifestyle alone, and pretending otherwise wastes years before adequate pharmacotherapy is started. The lifestyle interventions are nonetheless worth doing because they compound with pharmacotherapy and address other risk factors that ApoB does not capture.

How to actually get the test

If you have not had ApoB tested and you are over 35, the practical next step is to ask your primary care physician at your next visit. The exact request is "I'd like to add apolipoprotein B and lipoprotein-a to my next lipid panel." Both tests are available through major U.S. labs (Quest, LabCorp, Mayo) and through equivalent national lab networks in the UK, EU and most Asian markets. The fasting requirement is the same as for the standard lipid panel.

If your physician is unfamiliar with the request — which remains possible in primary care, particularly outside cardiology-focused practices — the test can also be ordered directly through online lab services like Quest Direct or Function Health for $40–$80 without a doctor's order, depending on jurisdiction.

The men who get this test in their thirties and forties have a meaningfully different prevention trajectory than the men who don't. The data has been on the table for half a decade. Most U.S. primary care has not caught up. The gap between the standard of care and the actual best practice is large enough that the responsibility for closing it has, in 2026, shifted toward the patient. Asking for the test is the move.